u/hedda_aguirre

Not to be pedantic but private plan and Canada are being used interchangeably and they are not interchangeable in real life.

Yeah, maintenance is the boring part and the important part.

the lowest dose you can stay on is not the lowest dose that works

Regain on a taper is expected. 19% back over 23 weeks, which matches the discontinuation data. Planned for it.

Yeah, maintenance is the boring part and the important part.

REDEFINE phase 18 readouts are interesting but 18 person CagriSema is different from 18 trial CagriSema.

Yeah, amylin is doing different work than GLP-1.

REDEFINE phase 9 readouts are interesting but 9 person amylin is different from 9 trial amylin.

prior auth criteria are state-specific, prior authorization differs

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

My version of this: I was so worried about the injection that I put it off for eleven days. The injection is the easiest part.

Was that the vendor COA or your own test?

Yeah, maintenance is the boring part and the important part.

the plateau is where the learning happens

the VendorInvestigate and PeptideMeter results differ by 10 points, both inside inter-lab variance

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

long-acting amylin is CagriSema, different satiety profile

Strongly agree.

Yes, exactly this, and it is the bit that took me 20 weeks to accept.

Australia here. Waited 21 months on a list, gave up, went private, and the total cost was roughly what I expected.

My version of this: I was so worried about the injection that I put it off for eleven days. The injection is the easiest part.

Mechanistically the bit that matters is dose stretching. It explains most of the early profile and a decent chunk of the outcome.